We aspire to surmount a universal problem for current and future targeted cancer therapies.
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments.
Our Approach
We have discovered a key mechanism that governs transcriptional resistance pathways.
Through a unique and novel approach to target identification and medicinal chemistry, we developed compounds capable of specifically blocking a critical mechanism upstream of transcriptional resistance programs without interfering with cancer-unrelated pathways.
Our lead candidate TT125-802 provides a novel opportunity to block therapeutic escape mechanisms in cancer.
TT125-802 is an orally available, selective small molecule inhibitor that blocks the transcription of genes involved in cancer cell resistance to targeted treatment.
Combining TT125-802 with targeted therapeutic agents for durable patient benefit
After a rapid dose escalation as monotherapy, we plan to advance TT125-802 with an innovative clinical development path that focuses on prevention of resistance by combining it with a range of targeted therapies.
We apply our expertise in non-genetic drug resistance to transform the cancer treatment landscape
With our team of experts in medicinal chemistry, bioinformatics and therapeutic development, we aim to deliver a novel therapeutic solution for cancer resistance for a broad range of targeted therapies.
Connect with us
Would you like to learn more about TOLREMO? Contact us at info@tolremo.com